Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

In accordance with 37 C.F.R. § 1.121(c), please cancel claims 2, 3, 7, 9 and 10 and amend claims 1, 4, 5 and 8 as follows (the marked up version of the amended claims follows the Remarks).

1. (Amended) A method of treatment of dementia and/or regression of cognitive function in a human or non human mammal in need of such treatment comprising the co-administration of pharmaceutically effective amounts of telmisartan and ramipril.

2-3. (Cancelled)

4. (Amended) The method of claim 1, wherein the telmisartan is administered in a daily dosage of 0.018 mg/kg to 6.429 mg/kg orally or of about 0.286 mg/kg parenterally and the ramipril is administered in a daily dosage of 0.143 mg/kg to 7.143 mg/kg orally or of about 0.286 mg/kg parenterally.

5. (Amended) The method of claim 4, wherein the telmisartan is administered in a daily dosage of 0.071 mg/kg to 1.429 mg/kg orally and the ramapril is administered in a daily dosage of 0.286 mg/kg to 1.429 mg/kg.

6. (Amended) The method of claim 1, wherein the telmisartan is administered in a daily dosage of 0.036 mg/kg to 0.143 mg/kg orally and the ramapril is administered in a daily dosage of 0.571 mg/kg to 1.143 mg/kg.

7. (Cancelled)

8. (Amended) A method for treating dementia and/or regression of cognitive function in the human or non-human body comprising the administration of telmisartan in an amount of 40 mg to 80 mg and ramipril in an amount of 2.5 mg to 10 mg in single dosage units for simultaneous, separate or sequential use in treatment of said indications, optionally together with one or more pharmaceutically acceptable diluents and/or carriers.—

9-10. (Cancelled)